Yttrium-90 delivers the most energetic beta-particle spectrum among clinically deployed therapeutic radionuclides, with a maximum energy of 2.28 MeV and a tissue penetration reaching 12 mm—enabling potent crossfire irradiation of large, heterogeneous tumors that smaller-range emitters cannot effectively treat. Protheragen offers comprehensive Y-90 radiolabeling solutions encompassing chelator-vector conjugation, automated synthesis for both microsphere and molecular platforms, and full preclinical validation—including matched 86Y/90Y theranostic dosimetry—to advance your high-energy beta therapy program from radiochemical concept to clinical administration.
Yttrium-90 (90Y) is a pure beta-emitting radionuclide with a physical half-life of 64.1 hours (2.67 days) and a maximum beta-particle energy of 2.28 MeV, corresponding to a mean tissue penetration of approximately 2.5 mm and a maximum range of roughly 11–12 mm in soft tissue. Unlike theranostic radionuclides such as 177Lu or 225Ac, 90Y emits no gamma photons suitable for external imaging, making it a purely therapeutic entity that minimizes radiation exposure to healthcare personnel and bystanders. This high-energy, long-range beta emission creates a pronounced crossfire effect, enabling the destruction of antigen-negative tumor cells and poorly vascularized tumor regions adjacent to targeted cells—a property particularly advantageous for bulky, necrotic, or stromal-rich solid tumors where homogeneous antigen expression is rarely achieved.
Fig 1. Tandem 90Y/177Lu-DOTATATE therapy: Kaplan-Meier estimators of overall survival from the time of therapy (OS-T) and progression-free survival. (Kunikowska, Jolanta, et al., 2020)
The radiochemistry of 90Y centers on trivalent Y3+ coordination with macrocyclic or acyclic polyaminocarboxylate chelators. DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) remains the gold standard for peptide and small-molecule conjugates, forming complexes with log K values near 24.7 and exceptional kinetic inertness under physiological conditions. For antibody-based radioimmunotherapy, the acyclic chelator CHX-A''-DTPA (tiuxetan)—employed in the FDA-approved Zevalin regimen—offers room-temperature labeling compatibility with temperature-sensitive immunoglobulins, albeit with marginally lower serum stability compared to DOTA. Emerging chelator platforms including octapa (picolinic acid-based) and 3,4,3-LI(1,2-HOPO) (hydroxypyridinone-based) have demonstrated rapid room-temperature 90Y labeling (>95% yield in 15 minutes) and superior in vivo retention in preclinical models, potentially addressing the renal accumulation observed with conventional DTPA and DOTA complexes. Standard labeling conditions for DOTA-based 90Y conjugates typically employ 0.5 M ammonium acetate or sodium acetate buffer at pH 5.0–7.5, with reaction times of 15–30 minutes at 25–37°C for antibodies and 80–95°C for heat-stable peptides.
Protheragen functions as a full-spectrum radiopharmaceutical CRDMO and CRO with specialized expertise in the unique radiochemical and dosimetric demands of high-energy beta-emitting therapeutics. Our Y-90 platform spans the entire development continuum—from chelator synthesis and vector conjugation for molecularly targeted constructs, through automated radiolabeling and microsphere quality control, to comprehensive preclinical evaluation including 86Y/90Y matched-pair theranostic imaging, Cherenkov luminescence monitoring, and combination therapy design with immune checkpoint inhibitors. Whether your program targets locoregional liver malignancies via SIRT, hematologic malignancies via radioimmunotherapy, or solid tumors via peptide receptor radionuclide therapy, we engineer each engagement to exploit the long-range crossfire and pure beta profile of 90Y while mitigating the bone marrow and renal toxicities historically associated with this radionuclide.
We engineer DOTA, CHX-A''-DTPA, octapa and HOPO chelator-vector precursors for antibodies, peptides and small molecules to boost Y-90 complex stability and lower renal/hepatic uptake. We optimize Y-90 radiolabeling for antibodies (25–37°C) and peptides (80–95°C) to achieve >95% radiochemical yield, and support characterization of glass and resin microspheres for local delivery.
We perform 90Y quality control via ITLC-SG, radio-HPLC and solid-phase extraction to test purity, molar activity and free Y³⁺ levels. In vitro assays include serum/plasma stability, metal transchelation challenge, cell uptake and immunoreactivity verification of labeled biomolecules.
We use Cherenkov luminescence imaging and 86Y/90Y matched-pair PET to map 90Y tumor distribution. Time-resolved organ biodistribution data are collected to calculate absorbed radiation doses for bone marrow, kidneys and liver.
We evaluate 90Y therapeutics in CDX, PDX and syngeneic tumor models, including monotherapy and combination regimens with immunotherapy, targeted drugs or chemotherapy. Hematologic and hepatic toxicity data are documented following GLP-aligned standards.
Our Y-90 radiolabeling workflow is calibrated to the dual demands of high-energy beta therapy: maximizing radiochemical yield and complex stability while managing the radiolytic sensitivity of biological vectors and the absence of gamma emissions for real-time reaction monitoring.
Step 1: Chelator & Vector Selection — Selection of DOTA, CHX-A''-DTPA, octapa, or HOPO based on vector thermal stability and intended indication; computational modeling of Y3+ coordination geometry; and organic synthesis with confirmed conjugation ratio and preserved binding affinity.
Step 2: Precursor Analytical Characterization — HPLC-UV, mass spectrometry, and endotoxin screening of the unlabeled conjugate; verification of peptide content, purity, and metal-binding capacity; and batch-to-batch consistency assessment prior to radiolabeling.
Step 3: Isotope Receipt & Qualification — Verification of 90Y radionuclidic purity; assessment of 90Sr breakthrough for generator-produced material; activity calibration against NIST-traceable standards; and decay-corrected scheduling aligned to the 64.1-hour half-life.
Step 4: Radiolabeling Reaction — Complexation of 90Y with chelator-vector conjugate under optimized pH, buffer, and temperature conditions—mild conditions (25–37°C) for antibodies and elevated heat (80–95°C) for peptides; real-time reaction monitoring via ITLC; and specific activity optimization.
Step 5: Purification & Formulation — Size-exclusion, C18 Sep-Pak, or ion-exchange purification to remove uncomplexed 90Y and excess vector; formulation in physiological buffer with pH and osmolality adjustment; sterile filtration; and visual inspection.
Step 6: Comprehensive QC Release — Radiochemical purity by ITLC-SG (>95%) and confirmatory radio-HPLC; free Y3+ quantification (<2%); molar activity determination; pH, osmolality, and endotoxin screening; and sterility validation.
Step 7: Stability Validation — In vitro serum stability at 37°C over 72–96 hours with time-course HPLC and ITLC analysis; radiolytic stability under high-activity concentrations; competitive metal challenge assays; and, where applicable, preliminary in vivo biodistribution to confirm complex integrity.
Step 8: Preclinical Study Execution — Pharmacokinetic, Cherenkov imaging, efficacy, and toxicity evaluations in relevant tumor models; 86Y/90Y matched-pair dosimetry; combination therapy arm design; and comprehensive data packages for IND, CTA, or IIT submission.
Whether your program targets the liver through next-generation microsphere platforms, the lymphatic system through refined radioimmunotherapy constructs, or solid tumors through high-energy peptide receptor radionuclide therapy, Protheragen provides the specialized radiochemistry and preclinical capabilities to de-risk your Y-90 development path. Contact our beta-emitter development team today to discuss your Y-90 radiolabeling requirements, from exploratory chelation studies to comprehensive IND-enabling packages. Reach out to us and discover how our integrated CRDMO+CRO platform can transform your high-energy beta-emitter vision into a clinically validated therapeutic.
Reference